BackProvention Bio Overview

Provention Bio Total Revenue

Track Provention Bio's total revenue ($13M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$10.81M
1408.09% YoY

As of Dec 2022

Annual Revenue (TTM)

$12.89M
824.37% YoY

Trailing 12 months ending Dec 2022

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Provention Bio (PRVB) FAQ

The latest total revenue for PRVB is $13M as of December 2022. That compares with $1.4M in the prior-year period — up 824.4% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Provention Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, PRVB's total revenue moved from $1.4M to $13M — a 824.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Provention Bio's operating scale or balance-sheet position.

Against Healthcare companies, PRVB currently prints $13M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Provention Bio's growth, margins, and balance sheet.

A total revenue figure of $13M for PRVB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting PRVB's total revenue ($13M), review year-over-year change from $1.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.